Clinical Efficacy and Safety of R-CDOP Regimen for Treatment of Newly Treated DLBCL Patients with Adverse Prognostic Factors.
10.19746/j.cnki.issn.1009-2137.2019.04.024
- Author:
Fu-Li YANG
1
;
Ming-Liang SHI
1
;
Xi-Feng WU
2
;
Jiu-De QI
3
Author Information
1. Department of Oncology,People's Hospital of Jinan City, Jinan 271199, Shandong Province, China.
2. Department of Hematology,People's Hospital of Jinan City, Jinan 271199, Shandong Province, China.
3. Department of Oncology,People's Hospital of Jinan City, Jinan 271199, Shandong Province, China,E-mail：13963449118@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
adverse effects;
Cyclophosphamide;
Disease-Free Survival;
Humans;
Lymphoma, Large B-Cell, Diffuse;
drug therapy;
Prognosis;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2019;27(4):1143-1148
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical efficacy and Safety of R-CDOP regimen for treatment of newly diagnosed DLBCL patients with adverse prognostic factors.
METHODS:The clinical data of 94 patients who suffered from DLBCL and received treatment with R-CDOP regimen, from October 2013 to February 2018 were collected and analyzed retrospectively. The clinical efficacy, survival benifits and safety, as well as the OS and PFS were compared according to clinical features.
RESULTS:After treatment of 94 cases with R-CDOP regimen, 73 cases reachived CR, 14 cases reachived PR, 2 cases were in SD and 4 cases were in PD, the ORR was 92.55% (87/94). The OS rate and PFS rate in followed-up 1 year were 94.68%（89/94） and 85.11%（80/94） separately, However, the median OS and PFS were not reached. There was no significant difference in the followed-up cumulative OS rate and PFS rate between patients with different Age, Ann-Arbor stage, IPI score, number of extranodal tumors, tumor diameter, expression of Ki-67 and LDH level and tissue involvement status（P>0.05）. There was no significant difference in the 1 years PFS rate and OS rate between patients with number of extranodal tumors for 0-1 and ≥2（P>0.05）. There was no significant difference in the 1 years PFS rate and OS rate between patients with tumor diameter for <7.5 cm and ≥7.5 cm（P>0.05）.
CONCLUSION:The R-CDOP regimen in the treatment of newly diagnosed DLBCL patients with poor prognostic factors can efficiently improve the early clinical efficacy, prolong the survival time and possess good safety, but the clinical prognosis for long-term remains to be observed.
